Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Caris Life SciencesCAI -3.22%12 EV-to-EBITDA is 34.66 as of Aug. 12, 2026, which is 38% above its 10-year median of 25.04. GuruFocus rates CAI with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 398 Biotechnology companies, Caris Life Sciences ranks worse than 76.38% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Caris Life Sciences's enterprise value is $5,985.2 Mil.
Caris Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $172.7 Mil. Therefore, Caris Life Sciences's EV-to-EBITDA for today is 34.66.
The historical rank and industry rank for Caris Life Sciences's EV-to-EBITDA or its related term are showing as below:
CAI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -90.4 Med: 25.04 Max: 675.27
Current: 34.66
During the past 4 years, the highest EV-to-EBITDA of Caris Life Sciences was 675.27. The lowest was -90.40. And the median was 25.04.
CAI's EV-to-EBITDA is ranked worse than 76.38% of 398
companies
in the Biotechnology industry
Industry Median: 13.395
vs CAI: 34.66
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Caris Life Sciences (NAS:CAI) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Caris Life Sciences's PE Ratio (TTM) for today is calculated as:
Caris Life Sciences's share price for today is $22.385.
Caris Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.360.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Caris Life Sciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Caris Life Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caris Life Sciences EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Caris Life Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Caris Life Sciences's EV-to-EBITDA falls into.
Caris Life Sciences's current Enterprise Value is $5,985.2 Mil.
Caris Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $172.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caris Life Sciences (CAI) has a EV-to-EBITDA of 34.66 as of Aug. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Caris Life Sciences. This is 38% above median its historical median of 25.04. According to the industry distribution chart, Caris Life Sciences ranks #304 out of 398 companies in the Biotechnology industry, placing it in the top 76.4%.
Is Caris Life Sciences' EV-to-EBITDA too high?
Caris Life Sciences' current EV-to-EBITDA of 34.66 is 38% above median its 10-year median of 25.04. The Biotechnology industry median EV-to-EBITDA is 13.40. Caris Life Sciences' value of 34.66 is 158.8% above this industry median. Based on the distribution chart, Caris Life Sciences ranks #304 out of 398 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Caris Life Sciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Caris Life Sciences' EV-to-EBITDA compare to EWTX and TNGX?
According to the Biotechnology industry distribution chart, Caris Life Sciences ranks #304 out of 398 companies for EV-to-EBITDA. This places Caris Life Sciences in the lower half of its industry. The industry median EV-to-EBITDA is 13.40. Caris Life Sciences' value of 34.66 is 158.8% above this benchmark. While the company's 10-year median is 25.04 vs. the industry median of 13.40, Caris Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.40, based on 398 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caris Life Sciences's current EV-to-EBITDA of 34.66 is 158.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Caris Life Sciences. For the Biotechnology industry, the median EV-to-EBITDA is 13.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caris Life Sciences's current EV-to-EBITDA is 34.66, which is 38% above median its own 10-year median of 25.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caris Life Sciences stock overvalued right now?
Caris Life Sciences (CAI) has a current EV-to-EBITDA of 34.66. The current EV-to-EBITDA is 34.66, which is 38% above median its 10-year median of 25.04 and 158.8% above the Biotechnology industry median of 13.40. Caris Life Sciences' overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Caris Life Sciences (CAI), the current EV-to-EBITDA is 34.66 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
12GF Score
Get the complete analysis for CAI
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI has been successfully added to your 
